SOLICITATION NOTICE
B -- Prediagnostic levels of c-peptide, C-reative protein, leptin and adiponectin and risk of pancreatic cancer
- Notice Date
- 7/5/2007
- Notice Type
- Solicitation Notice
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- Reference-Number-NCI-70081-NV
- Response Due
- 7/16/2007
- Archive Date
- 7/31/2007
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), plans to procure prediagnostic levels of c-peptide, C-reactive protein, leptin, and adiponectin and risk of pancreatic cancer on a sole source basis with Sir Mortimer B. Davis Jewish General Hospital, 3755 Ch De La Cote Sainte Catherine, Montreal Quebec, Canada. The North American Industry Classification System Code is 541380 and the business size standard in $11M. The acquisition will be conducted under the procedures for acquiring commercial items authorized in FAR Part 12 in accordance with the authority to use simplified procedures for commercial requirements provided in FAR 13.5. The purpose of this procurement is to provide laboratory analysis of up to 627 Prostate, Lung, Ovarian, and Colorectal Cancer Study (PLCO) cohort stored serum samples. The laboratory methods for measuring c-peptide, C-reactive protein, leptin, and adiponectin concentrations are described below. These methods have been shown to be reliable as determined by blinded QC from other DCEG studies. Sir Mortimer B. Davis Jewish General Hospital shall: 1) Measure c-peptide, C-reactive protein, leptin, and adiponectin on ~627 PLCO stored serum samples; 2) C-peptide, leptin, and high sensitivity C-reactive protein (duplicate measures) will be analyzed by enzyme-linked immunosorbent assays (ELISA) with reagents from Diagnostic Systems Laboratory (Webster, TX); 3) Adiponectin (duplicate measures) will be measured using ELISA using reagents from Millipore formerly Linco Inc. (Charles, MO); and 4) The samples will be sent boxed in batches. All batches and samples within the batches should be assayed in the order provided by NCI. The results of the analysis will be compared to results from a previous requirement (MQ613017) analyzing specimens from the Alpha-Tocopherol, Beta-Carotene Study cohort to investigate the relationship between c-peptide, adiponectin, and C-reactive protein and the risk of developing pancreatic cancer. Sir Mortimer B. Davis Jewish General Hospital is the only vendor who can perform these analytes and insure the results from this study are comparable to the aforementioned study. It is essential that analysis be performed in a single laboratory, under identical testing conditions, for the data are to be comparable and scientifically valid. To introduce another testing laboratory would be detrimental to the continuity of the research in progress. The Sir Mortimer B. Davis Jewish General Hospital is the only vendor known to the DCEG that can process these samples without the introduction of new variables into ongoing research. This is not a request for competitive quotation. However, if any interested party believes it can perform the requirement as detailed they may submit a statement of capabilities. The statement of capabilities and any other furnished information must be in writing and must contain material in sufficient detail to allow the NCI researcher to determine if the party can perform this requirement. An original and one copy of the capability statement must be received in the contracting office by 1:00 pm EDT, on July 16, 2007. Faxed and emailed capability statements are NOT authorized. All questions must be in writing and must be emailed to Melissa Marino at marinome@mail.nih.gov and Debbie Moore at dm170b@nih.gov or faxed (301) 402-4513. It is the vendor?s responsibility to call (301) 402-4509 and verify that questions were received. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award from the NCI contractors must be registered in the Online Representations and Certifications Applications (ORCA). Please refer to http://orca.bpn.gov In addition; contractors must be registered in the Central Contractor Registration (CCR) www.ccr.gov. No collect calls will be accepted.
- Record
- SN01335040-W 20070707/070705220455 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |